Posted by Michael Wonder on 22 Dec 2020
FDA approves paediatric indication for Xeomin (incobotulintoxinA) for the treatment of chronic sialorrhoea
21 December 2020 - Xeomin is the first and only neuromodulator approved in the U.S. to treat paediatric patients with chronic sialorrhea.
Merz Therapeutics announced today that the U.S. FDA has approved a supplemental biologics license application for Xeomin (incobotulinumtoxinA) for the treatment of patients aged 2 years and older with chronic sialorrhoea, or drooling.
Xeomin is the first and only FDA approved neuromodulator with this indication and was granted a priority review designation upon acceptance by the FDA.
